Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents
Authors:
Open Access
- 29 November 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (4) , 379-381
Abstract
Gabriele Roccuzzo, Luca Mastorino, Sara Susca, Caterina Cariti, Stefania G Passerini, Nadia Sciamarrelli, Silvia Borriello, Nicole Macagno, Niccolò Sliquini, GiKeywords
This publication has 6 references indexed in Scilit:
- Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyAmerican Journal of Clinical Dermatology, 2022
- Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective studyJournal of Dermatological Treatment, 2022
- Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective studyDermatologic Therapy, 2021
- Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective studyJournal of Dermatological Treatment, 2021
- Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech RepublicDermatology and Therapy, 2021
- Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data of a real‐life 16‐week retrospective studyDermatologic Therapy, 2020